Patents by Inventor Andrew Michael Ratz

Andrew Michael Ratz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aromatic ether derivatives useful as thrombin inhibitors
    Patent number: 7700628
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: April 20, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ankush Baburao Argade, Theodore Goodson, Jr., David Kent Herron, Sajan Joseph, Salvatore Donato Lepore, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Anne Louise Tebbe, Michael Robert Wiley, Ying Kwong Yee
  • Antithrombotic diamides
    Patent number: 7666866
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Valentine Joseph Klimkowski, Angela Lynn Marquart, John Joseph Masters, David Mendel, Andrew Michael Ratz, Gerald Floyd Smith, Michael Robert Wiley, Ying Kwong Yee
  • Antithrombotic ethers
    Patent number: 7615568
    Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: November 10, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Jared Harris Linebarger, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Leland Otto Weigel, Michael Robert Wiley, Ying Kwong Yee
  • AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS
    Publication number: 20090227566
    Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).
    Type: Application
    Filed: November 10, 2005
    Publication date: September 10, 2009
    Inventors: Ankush Baburao Argade, Theodore Goodson, JR., David Kent Herron, Sajan Joseph, Salvatore Donato Lepore, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Anne Lousie Tebbe, Michael Robert Wiley, Ying Kwong Yee
  • Antithrombotic aromatic ethers
    Patent number: 7511066
    Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: March 31, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, Theodore Goodson, Jr., David Kent Herron, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Michael Robert Wiley, Ying Kwong Yee
  • Antithrombotic Diamides
    Publication number: 20090062271
    Abstract: This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.
    Type: Application
    Filed: November 15, 2005
    Publication date: March 5, 2009
    Applicant: Eli Lilly And Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Valentine Joseph Klimkowski, Angela Lynn Marquart, John Joseph Masters, David Mendel, Andrew Michael Ratz, Gerald Floyd Smith, Michael Robert Wiley, Ying Kwong Yee
  • Antithrombotic Ethers
    Publication number: 20080108594
    Abstract: This application relates to a compound of formula I (or a pro-drug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).
    Type: Application
    Filed: April 13, 2004
    Publication date: May 8, 2008
    Applicant: Eli Lilly and Company
    Inventors: Jeffry Bernard Franciskovich, David Kent Herron, Jared Harris Linebarger, Angela Lynn Marquart, John Joseph Masters, David Mendel, Leander Merritt, Andrew Michael Ratz, Gerald Floyd Smith, Leland Otto Weigel, Michael Robert Wiley, Ying Kwong Yee
  • ?3 adrenergic agonists
    Patent number: 7208505
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: April 24, 2007
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Rushad Eruch Karanjawala, Cynthia Darshini Jesudason, Theo Schotten, Britta Evers, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Excitatory amino acid receptor antagonists
    Patent number: 7205313
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • 3-substituted oxindole ?3 agonists
    Patent number: 7087635
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz, Theo Schotten, Gerd Reuhter
  • Growth hormone secretagogues
    Patent number: 6992097
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • 3-substituted oxindole ?-3 agonists
    Patent number: 6911463
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • 3-substituted oxindole beta-3 agonists
    Publication number: 20040242668
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: February 11, 2004
    Publication date: December 2, 2004
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Excitatory amino acid receptor antagonists
    Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Growth Hormone secretagogues
    Publication number: 20040122234
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: June 3, 2003
    Publication date: June 24, 2004
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Growth hormone secretagogues
    Patent number: 6639076
    Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Process to make chiral compounds
    Patent number: 6008412
    Abstract: The present invention relates to processes for resolving N-methyl-3(R,S)-hydroxy-3-phenylpropylamine and N,N-dimethyl-3 (R,S) -hydroxy-3-phenylpropylamine with the isomers of mandelic acid and the resulting salts.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: December 28, 1999
    Assignee: Eli Lilly and Company
    Inventor: Andrew Michael Ratz